title: Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials.
abstract: Vaccination with viral vectors or adjuvants can induce early changes in circulating peripheral blood leukocytes that are predictive of a protective immune response. In this study, we define an 11-color whole blood antibody staining Trucount Panel (TP1) to enumerate and phenotype the major leukocyte populations in a human vaccine experimental medicine trial setting. TP1 can be prepared up to 8weeks prior to use, enabling bulk preparation at a central laboratory and distribution to clinical sites. Cells in whole blood must be stained within 4h of draw to accurately detect the major cell populations. Staining of cells with TP1 followed by storage and shipping at -80°C to a central laboratory has little to no effect on the cell concentrations observed. We also present data from an HIV vaccine multicenter clinical trial obtained using the optimized TP1 assay protocol and show that the data produced accurately correlates with complete blood count (CBC) data. Taken together, these data indicate the optimized TP1 panel assay can be used in a multicenter clinical trial setting to increase our understanding of systemic responses to vaccination or disease.
authors.affiliation: Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
authors.forename: Tiffany
authors.initials: T
authors.lastname: Hensley-McBain
authors.affiliation: Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
authors.forename: Antje
authors.initials: A
authors.lastname: Heit
authors.affiliation: Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA.
authors.forename: Stephen C
authors.initials: SC
authors.lastname: De Rosa
authors.affiliation: Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA; Department of Medicine, University of Washington, Seattle, WA 98195, USA.
authors.forename: M Juliana
authors.initials: MJ
authors.lastname: McElrath
authors.affiliation: Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Cape Town HVTN Immunology Laboratory, Hutchinson Center Research Institute of South Africa, Cape Town, South Africa. Electronic address: eanderse@hcrisa.org.za.
authors.forename: Erica
authors.initials: E
authors.lastname: Andersen-Nissen
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D001772:Blood Cell Count / Q000379:methods; D001793:Blood Preservation / Q000379:methods / Q000592:standards; D015925:Cryopreservation / Q000379:methods / Q000592:standards; D005260:Female; D006801:Humans; D007962:Leukocytes / Q000166:cytology / Q000276:immunology; D008297:Male; D013194:Staining and Labeling / Q000379:methods / Q000592:standards; D014611:Vaccination
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic
keywords: Assay optimization; Clinical trial; Experimental medicine trial; Multiparameter flow cytometry; Phenotyping; Trucount